The investigators of the anticipated ISCHEMIA trial have published a paper in Circulation: Cardiovascular Quality and Outcomes defending their late addition of “softer” outcomes to their primary composite endpoint.

DUBLIN — May 16, 2018 — Medtronic plc (NYSE: MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary interventions (PCI).

Using data from the randomized COURAGE trial, a team of researchers developed a model to predict one-year angina and quality-of-life outcomes among patients with stable coronary artery disease (CAD).

Preliminary research presented May 11 at the American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions 2018, suggests an injection may one day be able to reverse atherosclerosis.

Phillipsburg, NJ—INFINITT North America, an award-winning developer of image and data management solutions for healthcare, announced today that they have achieved certification from the American College of Cardiology (ACC), demonstrating that INFINITT Cardiology Suite-v. 1.0.8.1 meets NCDR requirements for version 5 of the CathPCI Registry®.

Each 50-meter increase in a six-minute walk test was associated with 20 percent lower odds of developing cognitive dysfunction after cardiac surgery, according to a single-center study from Japan published in The Annals of Thoracic Surgery.

Requiring hospitals and physicians to publicly report their mortality outcomes related to percutaneous coronary intervention (PCI) causes many interventional cardiologists to forego high-risk procedures, researchers reported in JAMA Cardiology.

United States veterans receiving invasive coronary procedures have become older and sicker over the past several years, but adjusted mortality rates for percutaneous coronary intervention (PCI) are in a slight decline.